NewHydrogen, Inc. 10-K

ITEM 9A. CONTROLS AND PROCEDURES. Evaluation of Disclosure Controls and Procedures. We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. These disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. 14 In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. As of December 31, 2021, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in our periodic reports is recorded, processed, summarized and reported, within the time periods specified for each report and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management’s Report of Internal Control over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule 13a - 15(f). Our internal control system was designed to provide reasonable assurance to our management and the Board of Directors regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control - Integrated Framework - Guidance for Smaller Public Companies (the COSO criteria). Based on our assessment we believe that, as of December 31, 2021, our internal controls over financial reporting is effective based on those criteria. This annual report does not include an attestation report by M&K CPAS, PLLC, our independent registered public accounting firm, regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to temporary rules of the SEC that permits the Company to only provide management’s report in this Form 10-K. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting that occurred during the fourth quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. ITEM 9B. OTHER INFORMATION. None. 15 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE The following table sets forth information about our executive officers, key employees and directors. Name Age Position David Lee 62 Chief Executive Officer, Acting Chief Financial Officer and Director Spencer Hall 45 Chief Operating Officer and Director The principal occupations for the past five years (and, in some instances, for prior years) of each of our executive officers and directors, are as follows: David Lee - Chief Executive Officer and Acting Chief Financial Officer and Director of the Company since inception (April 24, 2006). Dr. Lee has over 30 years of engineering, marketing, sales, and corporate management experience in the areas of military and consumer communication systems, automotive electronics, software development and consulting. From 2004 to 2006, he was with Ramsey-Shilling Co. in the business of Commercial Real Estate Investment and Brokerage. From 2000 to 2004, he served as Chief Operating Officer for Applied Reasoning, Inc., a Delaware company engaged in the business of Internet Software Development. From 1994 to 2000, he served as Vice Present and General Manager for RF-Link Technology, Inc., a California company engaged in the business of Wireless Technology Development and Manufacturing. Dr. Lee received a Ph.D. in Electrical Engineering from Purdue University in 1989, a Master of Science in Electrical Engineering from University of Michigan in 1986 and a Bachelor of Science in Electrical Engineering from the University of Texas at Austin in 1984. The Board of Directors has concluded that Dr. Lee is qualified to serve as a director of the Company because of his diverse experience in technology, marketing, and executive management. Spencer Hall – Chief Operating Officer and Director of the Company since February 8, 2021, Mr. Hall has held senior management positions over the course of his career including director of communications for PacifiCorp, a Berkshire Hathaway Energy-owned electric utility serving nearly two million customers across Oregon, California, Washington, Utah, Idaho and Wyoming. Prior to his role at PacifiCorp, he served as vice president of digital platforms for the Utah Jazz (Larry H. Miller Sports & Entertainment) and as news director of KSL.com, the largest news outlet in the Intermountain West. Hall holds a Master of Science in Instructional Design and Technology from Utah State University and a Bachelor of Arts in Visual Art from Brigham Young University. The Board of Directors has concluded that Mr. Hall is qualified to serve as a director of the Company because of his diverse experience in technology, marketing, and executive management. 16 COMMITTEES OF THE BOARD We currently do not maintain any committees of the Board of Directors. Given our size and the development of our business to date, we believe that the board through its meetings can perform all of the duties and responsibilities which might be performed by a committee. We do not currently have an audit committee financial expert. INDEBTEDNESS OF EXECUTIVE OFFICERS AND DIRECTORS No executive officer, director or any member of these individuals’ immediate families or any corporation or organization with whom any of these individuals is an affiliate is or has been indebted to us since the beginning of our last fiscal year. FAMILY RELATIONSHIPS There are no family relationships among our executive officers and directors. CODE OF ETHICS We have adopted a Code of Ethics that applies to all of our directors, officers and employees. The text of the Code of Ethics is filed as an exhibit to this annual report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission on March 25, 2008. The Company will provide to any person without charge, upon request to the Company at its office, a copy of the Code of Ethics. Any waiver of the provisions of the Code of Ethics for executive officers and directors may be made only by the Audit Committee and, in the case of a waiver for members of the Audit Committee, by the Board of Directors. Any such waivers will be promptly disclosed to our shareholders. LEGAL PROCEEDINGS During the past ten years, none of our directors, executive officers, promoters, control persons, or nominees has been: ● the subject of any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; ● convicted in a criminal proceeding or is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); ● subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or any Federal or State authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; ● found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law. ● the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of (a) any Federal or State securities or commodities law or regulation; (b) any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or (c) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or ● the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member. 17 Board Leadership Structure and Role in Risk Oversight Although we have not adopted a formal policy on whether the Chairman and Chief Executive Officer positions should be separate or combined, we have traditionally determined that it is in the best interests of the Company and its shareholders to combine these roles. Due to the small size and early stage of the Company, we believe it is currently most effective to have the Chairman and Chief Executive Officer positions combined. In addition, having one person serve as both Chairman and Chief Executive Officer eliminates potential for confusion and provides clear leadership for the Company, with a single person setting the tone and managing our operations. The Board oversees specific risks, including, but not limited to: ● appointing, retaining and overseeing the work of the independent auditors, including resolving disagreements between the management and the independent auditors relating to financial reporting; ● approving all auditing and non-auditing services permitted to be performed by the independent auditors; ● reviewing annually the independence and quality control procedures of the independent auditors; ● reviewing, approving, and overseeing risks arising from proposed related party transactions; ● discussing the annual audited financial statements with the management; ● meeting separately with the independent auditors to discuss critical accounting policies, management letters, recommendations on internal controls, the auditor’s engagement letter and independence letter and other material written communications between the independent auditors and the management; and ● monitoring the risks associated with management resources, structure, succession planning, development and selection processes, including evaluating the effect the compensation structure may have on risk decisions. Board of Directors Meetings and Attendance We have no formal policy regarding director attendance at the annual meeting of stockholders. The Board of Directors held eighteen (18) meetings in 2021 including three (3) meetings prior to filing our quarterly reports and one (1) meeting prior to filing this Annual Report. All Board members were present at all of the meetings. Section 16(a) Beneficial Ownership Reporting Compliance Section 16(a) of the Exchange Act requires the Company’s directors, executive officers and persons who own more than 10% of the Company’s stock (collectively, “Reporting Persons”) to file with the SEC initial reports of ownership and changes in ownership of the Company’s common stock. Reporting Persons are required by SEC regulations to furnish the Company with copies of all Section 16(a) reports they file. To the Company’s knowledge, based solely on its review of the copies of such reports received or written representations from certain Reporting Persons that no other reports were required, the Company believes that during its fiscal year ended December 31, 2021 all Reporting Persons timely complied with all applicable filing requirements. 18 ITEM 11. EXECUTIVE COMPENSATION. The following table summarizes all compensation recorded by us in each of the last two completed fiscal years for the named executive officers. Name and Principal Position Year Salary ($) Bonus ($) Stock Awards Option Awards ($) Non-Equity Incentive Plan Compensation ($) Non- Qualified Deferred Compensation All Other Compensation ($) Total ($) David Lee 2021 $ 0.232 - - 28.686 (1) - - - $ 28,918 - CEO and Acting CFO 2020 $ 0.156 - - - - - - $ 0.156 Spencer Hall – COO 2021 $ .157 3.652 (2) $ 3.809 $ - - - - - - - $ - (1) Calculated at fair value in accordance with the authoritative guidance provided by the Financial Accounting Standards Board, where the value of the stock compensation is based upon the grant date and recognized over the vesting period. On the grant date of February 18, 2021, half of the shares vested immediately, and the remaining half shall become exercisable in equal amounts over a twenty-four (24) month period during the term of the Optionee’s employment. On June 29, 2021, the Company repriced the options and recognized additional compensation expense per ASC 718. Mr. Lee was granted options to purchase 400,000,000 shares of common stock at an exercise price of $0.028, with a fair value of $28.686 million calculated using the Black Scholes method. (2) Calculated at fair value in accordance with the authoritative guidance provided by the Financial Accounting Standards Board, where the value of the stock compensation is based upon the grant date and recognized over the vesting period. On the grant date of February 18, 2021, the options shall become exercisable in equal amounts over a thirty-six (36) month period during the term of the Optionee’s employment. On June 29, 2021, the Company repriced the options and recognized additional compensation expense per ASC 718. Mr. Hall was granted options to purchase 50,000,000 shares of common stock at an exercise price of $0.028, with a fair value of $3.652 million calculated using the Black Scholes method. Employment Agreements The Company currently has no employment agreements with its executive officers. Employee Benefit Plans The Company currently has no benefit plans in place for its employees. Stock Option Plan The Company has no stock option plan. Director Compensation Directors receive compensation for their services and reimbursement for their expenses as shall be determined from time to time by resolution of the Board. Currently, our directors do not receive monetary compensation for their service on the Board of Directors. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. The following table sets forth, as of March 31, 2022, the number of and percent of our common stock beneficially owned by: ● all directors and nominees, naming them, ● our executive officers, ● our directors and executive officers as a group, without naming them, and ● persons or groups known by us to own beneficially 5% or more of our common stock: We believe that all persons named in the table have sole voting and investment power with respect to all shares of common stock beneficially owned by them. A person is deemed to be the beneficial owner of securities that can be acquired by him within 60 days from March 31, 2022 upon the exercise of options, warrants or convertible securities. Each beneficial owner’s percentage ownership is determined by assuming that options, warrants or convertible securities that are held by him, but not those held by any other person, and which are exercisable within 60 days of March 31, 2022 have been exercised and converted. Unless otherwise indicated, the address of each of the following beneficial owner is c/o NewHydrogen, Inc., 27936 Lost Canyon Road, Suite 202, Santa Clarita, CA 91387 Title of Class Name of Beneficial Owner Number of Shares of Common Stock Beneficially Owned Percentage of Common Stock Beneficially Owned(1 ) Common Stock David Lee (2) 341,769,285 32.5 % Common Stock Spencer Hall (3) 20,833,335 2.8 % All Executive Officers and Directors as a Group (2 individuals) 362,602,620 35.3 % 1. Based upon 715,496,051 shares of common stock outstanding as of March 31, 2022. 2. Includes 4,769,290 shares of common stock and 336,999,995 shares of common stock underlying options that are fully vested and that will vest within 60 days of the date of this report. 3. Includes 20,833,335 shares of common stock underlying options that are fully vested and that will vest within 60 days of the date of this report. 19 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE. There were no material related party transactions which we entered into during the last two fiscal years. Director Independence We currently do not currently have any directors who are “independent” as defined under the NASDAQ Marketplace Rules. ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES. Audit Fees The following table shows that fees that were billed to the Company by our independent registered public accounting firm for professional services rendered in 2021 and 2020. The audit fees represent fees for professional services performed by M&K CPAS, PLLC (“M&K”) as applicable, for the audit of our financial statements and the review of our quarterly financial statements, as well as services that are normally provided in connection with statutory and regulatory filings or engagements. Year Audit Fees Audit- Related Fees Tax Fees All Other Fees 2021 $ 22,000 $ - $ - $ - 2020 $ 22,000 $ - $ - $ - Audit-Related Fees We did not incur assurance and audit-related fees during 2021 and 2020, to M&K as applicable, nor in connection with the audit of our financial statements for the reviews of registration statements and issuance of related consents and assistance with SEC comment letters. Tax Fees We did not incur fees for tax compliance, tax advice, or tax planning for the years ended December 31, 2021 and 2020, respectively. All Other Fees There were no other fees billed to us by M&K as applicable, for services rendered to us during the years ended December 31, 2021 and 2020, respectively, other than the services described above under “Audit Fees” and “Audit-Related Fees.” As of the date of this filing, our current policy is to not engage our independent registered public accounting firm to provide, among other things, bookkeeping services, appraisal or valuation services, or international audit services. The policy provides that we engage our independent registered public accounting firm to provide audit and other assurance services, such as review of SEC reports or filings, as set forth above. 20 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES . Exhibit No. Description 3.1 Articles of Incorporation of BioSolar Labs, Inc. filed with the Nevada Secretary of State on April 24, 2006 (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006) 3.2 Certificate of Amendment to Articles of Incorporation of BioSolar Labs, Inc. filed with the Nevada Secretary of State on May 25, 2006 (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006) 3.3 Certificate of Amendment to Articles of Incorporation of BioSolar Labs, Inc. filed with the Nevada Secretary of State on June 8, 2006 (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006) 3.4 Certificate of Amendment to Articles of Incorporation of BioSolar Labs, Inc. filed with the Nevada Secretary of State on July 18, 2011 (Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 19, 2011) 3.5 Certificate of Amendment to Articles of Incorporation of BioSolar, Inc. filed with the Nevada Secretary of State on July 10, 2013 (Incorporated by reference to the Company’s Quarterly Report of Form 10-Q filed with the SEC on October 25, 2013) 3.6 Bylaws of BioSolar, Inc. (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006) 3.7 Certificate of Designations of Preferences Rights and Limitations of Series A Preferred Stock filed with the Nevada Secretary of State on October 29, 2019 (Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on November 1, 2019) 3.8 Certificate of Amendment to Articles of Incorporation of BioSolar, Inc. filed with the Nevada Secretary of State on December 10, 2019 (Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on December 12, 2019) 3.9 Certificate of Designations of Preferences Rights and Limitations of Series B Preferred Stock filed with the Nevada Secretary of State on January 15, 2021 (Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on January 20, 2021) 3.10 Certificate of Designation filed with the Nevada Secretary of State on March 11, 2021 (Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on March 12, 2021) 3.11 Certificate of Designations of Preferences Rights and Limitations of Series D Preferred Stock filed with the Nevada Secretary of State on April 14, 2021 (Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 19, 2021) 3.12 Articles of Conversion/Exchange/Merger filed with the Nevada Secretary of State on April 28, 2021 (Incorporated by reference to the Company’s Current Report on Form 8-k filed with the SEC on May 3, 2021) 3.13 Certificate to Accompany Amended and Restated Articles filed on June 9, 2021 (Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 11, 2021) 4.1 Description of Registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (filed herewith). 10.7 Joint Development Agreement with Silico Ferrosolar SLU dated as of June 14, 2018 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on June 19, 2018 21 10.52 Convertible Promissory Note dated as of January 14, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 20, 2021) 10.53 Securities Purchase Agreement dated as of January 14, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 20, 2021) 10.54 Engagement Letter dated as of January 22, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 25, 2021) 10.55 Form of Securities Purchase Agreement dated as of January 24, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 25, 2021) 10.56 Form of Warrant dated as of January 24, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 25, 2021) 10.57 Form of Registration Rights Agreement dated as of January 24, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 25, 2021) 10.58 Form of Placement Agent Warrant dated as of January 24, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 25, 2021) 10.59 Form of Pre-Funded warrant dated as of January 24, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 25, 2021) 10.60 Securities Purchase Agreement dated as of March 9, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 12, 2021) 10.61 Form of Securities Purchase Agreement dated as of April 4, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on April 6, 2021) 10.62 Form of Common Warrant dated as of April 4, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on April 6, 2021) 10.63 Form of Pre-Funded Warrant dated as of April 4, 2021 (Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on April 6, 2021) 14.1 Code of Ethics (Incorporated by reference to the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2008) 31.1 Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to Sarbanes-Oxley Section 302 (filed herewith). 32.1 Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (filed herewith). EX-101.INS Inline XBRL Instance Document EX-101.SCH Inline XBRL Taxonomy Extension Schema Document EX-101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase EX-101.DEF Inline XBRL Taxonomy Extension Definition Linkbase EX-101.LAB Inline XBRL Taxonomy Extension Labels Linkbase EX-101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase 22 ITEM 16. FORM 10-K SUMMARY None 23 SIGNATURES In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on March 31, 2022. NEWHYDROGEN, INC. By: /s/ David Lee CHIEF EXECUTIVE OFFICER (PRINCIPAL EXECUTIVE OFFICER) AND ACTING CHIEF FINANCIAL OFFICER (ACTING PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER) Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated: SIGNATURE TITLE DATE /s/ DAVID LEE CHIEF EXECUTIVE OFFICER March 31, 2022 DAVID LEE (PRINCIPAL EXECUTIVE OFFICER), ACTING CHIEF FINANCIAL OFFICER (PRINCIPAL ACCOUNTING AND FINANCIAL OFFICER) AND CHAIRMAN OF THE BOARD /s/ SPENCER HALL CHIEF OPERATING OFFICER AND DIRECTOR SPENCER HALL March 31, 2022 24 INDEX TO FINANCIAL STATEMENTS NEWHYDROGEN, INC. FINANCIAL STATEMENTS CONTENTS Page Report of Independent Registered Public Accounting Firm - M&K CPAS, PLLC (PCAOB ID: 2738 ) F-1 Balance Sheets as of December 31, 2021 and December 31, 2020 F-2 Statements of Operations for the years ended December 31, 2021 and 2020 F-3 Statement of Shareholders’ Deficit for the years ended December 31, 2021 and 2020 F-4 Statements of Cash Flows for the years ended December 31, 2021 and 2020 F-5 Notes to Financial Statements F-6 - F-18 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of NewHydrogen, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of NewHydrogen, Inc. (the Company) as of December 31, 2021 and 2020, and the related statements of operations, shareholders’ deficit, and cash flows for the two-year period then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB . We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and the significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe our audits provide a reasonable basis for our opinion. Critical Audit Matters The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinion on the critical audit matters or on the accounts or disclosures to which they relate. As discussed in Note 2 to the financial statements, the Company issues stock-based compensation in accordance with ASC 718, Compensation. Auditing management’s calculation of the fair value of stock-based compensation can be a significant judgment given the fact that the Company uses management estimates on various inputs to the calculation. Auditing a specialist’s calculation of the value of derivatives can be a significant judgment given the fact that the Company uses the specialists estimates on various inputs to the calculation. /s/ M&K CPAS, PLLC M&K CPAS, PLLC We have served as the Company’s auditor since 2019 Houston, TX F- 1 NEWHYDROGEN, INC. BALANCE SHEETS December 31, 2021 December 31, 2020 ASSETS CURRENT ASSETS Cash $ 6,645,710 $ 63,496 Prepaid expenses 12,023 55,435 TOTAL CURRENT ASSETS 6,657,733 118,931 PROPERTY AND EQUIPMENT Machinery and equipment 37,225 37,225 Less accumulated depreciation ( 33,366 ) ( 32,023 ) NET PROPERTY AND EQUIPMENT 3,859 5,202 OTHER ASSETS Patents, net of amortization of $ 18,134 and $ 15,112 , respectively 27,202 30,224 Deposit 770 770 TOTAL OTHER ASSETS 27,972 30,994 TOTAL ASSETS $ 6,689,564 $ 155,127 LIABILITIES AND SHAREHOLDERS’ DEFICIT CURRENT LIABILITIES Accounts payable $ 1,780 $ - Accrued expenses - 991,716 Derivative liability - 148,590,100 Convertible promissory notes net of debt discount of $ 0 and $ 219,850 , respectively - 1,069,974 TOTAL CURRENT LIABILITIES 1,780 150,651,790 LONG TERM LIABILITIES Convertible promissory notes net of debt discount of $ 0 and $ 0 , respectively - 1,418,225 TOTAL LONG TERM LIABILITIES - 1,418,225 TOTAL LIABILITIES 1,780 152,070,015 COMMITMENT AND CONTINGENICES (See Note 9) - - Series C Convertible Preferred Stock, 34,853 and 0 shares outstanding, respectively, redeemable value of $ 3,485,313 and $ 0 , respectively 3,485,313 - SHAREHOLDERS’ EQUITY Preferred stock, $ 0.0001 par value; 10,000,000 authorized shares; - - Common stock, $ 0.0001 par value; 3,000,000,000 authorized shares 715,496,051 and 456,198,529 shares issued and outstanding, respectively 71,549 45,620 Preferred treasury stock, 0 and 1,000 shares outstanding, respectively - - Additional paid in capital 164,000,447 13,114,993 Accumulated deficit ( 160,869,525 ) ( 165,075,501 ) TOTAL SHAREHOLDERS’ EQUITY (DEFICIT) 3,202,471 ( 151,914,888 ) TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 6,689,564 $ 155,127 The accompanying notes are an integral part of these audited financial statements F- 2 NEWHYDROGEN, INC. STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 December 31, 2021 December 31, 2020 Years Ended December 31, 2021 December 31, 2020 REVENUE $ - $ - OPERATING EXPENSES General and administrative expenses 51,229,031 447,665 Research and development 1,221,134 177,722 Depreciation and amortization 4,365 4,365 TOTAL OPERATING EXPENSES 52,454,530 629,752 LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES) ( 52,454,530 ) ( 629,752 ) OTHER INCOME/(EXPENSES) Interest income 3,632 75 Gain on settlement of debt and derivatives 93,180,986 - Gain (Loss) on change in derivative liability ( 29,966,084 ) ( 139,038,754 ) Interest expense ( 574,524 ) ( 876,229 ) TOTAL OTHER INCOME (EXPENSES) 62,644,010 ( 139,914,908 ) NET INCOME (LOSS) $ 10,189,480 $ ( 140,544,660 ) BASIC EARNINGS (LOSS) PER SHARE $ 0.02 $ ( 0.50 ) DILUTED EARNING (LOSS) PER SHARE $ 0.00 $ ( 0.50 ) WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC 651,573,767 280,952,034 DILUTED 1,117,523,767 280,952,034 The accompanying notes are an integral part of these audited financial statements F- 3 NEWHYDROGEN, INC. STATEMENTS OF SHAREHOLDERS’ DEFICIT FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 Shares Amount Shares Amount Capital Deficit Total YEAR ENDED DECEMBER 31, 2020 Preferred Stock Common Stock Additional paid-in Accumulated Shares Amount Shares Amount Capital Deficit Total Balance at December 31, 2019 - $ - $ 133,912,520 $ 13,391 $ 12,301,739 $ ( 24,530,841 ) $ ( 12,215,711 ) Issuance of common shares for cash Issuance of common shares for cash, shares Issuance of common shares for converted promissory notes and accrued interest - - 322,286,009 32,229 813,254 - 845,483 Issuance of commons shares for services Issuance of commons shares for services, shares Fair value of convertible notes and accrued interest in exchanged for Series C Preferred Stock Fair value of convertible notes and accrued interest in exchanged for Series C Preferred Stock, shares Issuance of 3,Series C Preferred stock Issuance of common shares for conversion of preferred stock Issuance of common shares for conversion of preferred stock, shares Stock compensation cost Issuance of common stock warrants deemed dividends Rounding Net Loss - - - - - ( 140,544,660 ) ( 140,544,660 ) Balance at December 31, 2020 - $ - 456,198,529 $ 45,620 $ 13,114,993 $ ( 165,075,501 ) $ ( 151,914,888 ) YEAR ENDED DECEMBER 31, 2021 Preferred Stock Common Stock Additional Paid-in Accumulated Shares Amount Mezzanine Shares Amount Capital Deficit Total Balance at December 31, 2020 - $ - $ - $ 456,198,529 $ 45,620 $ 13,114,993 $ ( 165,075,501 ) $ ( 151,914,888 ) Issuance of common shares for cash - - - 208,333,334 20,833 8,763,867 - 8,784,700 Issuance of common shares for converted promissory notes and accrued interest - - - 21,964,188 2,196 203,779 - 205,975 Issuance of commons shares for services - - - 1,000,000 100 149,700 - 149,800 Fair value of convertible notes and accrued interest in exchanged for Series C Preferred Stock - - - 85,555,201 - 85,555,201 Issuance of, Series C Preferred stock - - 3,485,313 - - - - - Issuance of common shares for conversion of preferred stock - - 28,000,000 2,800 ( 2,800 ) - - Stock compensation cost - - - - - 50,232,202 - 50,232,202 Issuance of common stock warrants deemed dividends - - - - - 5,983,504 ( 5,983,504 ) - Rounding - - - - 1 - 1 Net Income - - - - - - 10,189,480 10,189,480 Net Income (loss) 10,189,480 10,189,480 Balance at December 31, 2021 - $ - $ 3,485,313 715,496,051 $ 71,549 $ 164,000,447 $ ( 160,869,525 ) $ 3,202,471 The accompanying notes are an integral part of these audited financial statements F- 4 NEWHYDROGEN, INC. STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 December 31, 2021 December 31, 2020 Years Ended December 31, 2021 December 31, 2020 CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss) $ 10,189,480 $ ( 140,544,660 ) Adjustment to reconcile net income(loss) to net cash (used in) provided by operating activities Adjustment to reconcile net income(loss) to net cash (used in) provided by operating activities Depreciation and amortization expense 4,366 4,365 Common stock issued for services 149,800 - Stock compensation expense 50,232,202 - (Gain) Loss on net change in derivative liability 29,966,084 139,038,754 Amortization of debt discount recognized as interest expense 455,989 611,856 Gain on settlement of debt and derivative ( 93,180,986 ) - (Increase) Decrease in Changes in Assets Prepaid expenses 43,411 ( 25,479 ) Increase (Decrease) in Changes in Liabilities Accounts payable 1,780 ( 58 ) Accrued expenses 53,388 267,924 NET CASH USED IN OPERATING ACTIVITIES ( 2,084,486 ) ( 647,298 ) CASH FLOWS FROM INVESTING ACTIVITIES: - - CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds for the sale of common stock for cash 8,784,700 - Principal payments on convertible debt ( 310,000 ) - Net proceeds from convertible promissory notes 192,000 649,000 NET CASH PROVIDED BY FINANCING ACTIVITIES 8,666,700 649,000 NET INCREASE IN CASH 6,582,214 1,702 CASH, BEGINNING OF YEAR 63,496 61,794 CASH, END OF YEAR $ 6,645,710 $ 63,496 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Interest paid $ 455,989 $ 925 Taxes paid $ - $ - SUPPLEMENTAL SCHEDULE OF NON-CASH TRANSACTIONS Common stock issued for convertible notes and accrued interest $ 205,975 $ 845,483 Fair value of initial derivative $ 180,004 $ 632,144 Fair value of preferred stock in exchange of convertible notes $ 85,555,201 $ - Issuance of common stock warrants deemed dividends $ 5,983,504 $ - The accompanying notes are an integral part of these audited financial statements F- 5 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 1. Basis of Presentation Organization NewHydrogen, Inc. (the “Company”) was incorporated in the state of Nevada on April 24, 2006.  The Company, based in Santa Clarita, California, began operations on April 25, 2006 to develop and market Photovoltaic solar technology products.    Line of Business We are a developer of clean energy technologies. Our current focus is on developing an electrolyzer technology to lower the cost of Green Hydrogen production. We are developing technologies to significantly reduce or replace rare earth materials with inexpensive earth abundant materials in electrolyzers to help usher in a Green Hydrogen economy. We previously developed BioBacksheet R , a high performance green back sheet for Photovoltaic solar modules., Going Concern Substantial Doubt Alleviated As of the year ended December 31, 2021, the Company had income of $ 10,189,480 . As of December 31, 2021, its accumulated deficit was $ 160,869,525 . Management believes the Company’s present cash flows will enable it to meet its obligations for twenty four months from the date these financial statements are available to be issued. Management will continue to obtain new equity financing. It is probable that management will continue to obtain new sources of financing that will enable the Company to meet its obligations for the twelve-month period from the date the financial statements are available to be issued. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements. Revenue Recognition The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. The Company adopted Accounting Standards Codification (“ASC”) 606, whereby revenue will be recognized as performance obligations are satisfied and customers obtain control of goods or services. However, in the event of a loss on a sale is foreseen, the Company will recognize the loss as it is determined. To date, the Company has not had significant revenues and is in the development stage. Cash and Cash Equivalent The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Concentration Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Company (FDIC) limits. At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of December 31, 2021, the cash balance in excess of the FDIC limits was $ 6,395,710 . The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements, include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, derivative liabilities and the fair value of stock options. Actual results could differ from those estimates. Property and Equipment Property and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT Computer equipment 5 Years Machinery and equipment 10 Years Depreciation expense for the years ended December 31, 2021 and 2020 was $ 1,342 and $ 2,098 , respectively. F- 6 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Intangible Assets The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful lives. SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES Useful Lives 12/31/2021 12/31/2020 Patents $ 45,336 $ 45,336 Less accumulated amortization 15 years ( 18,134 ) ( 15,112 ) Intangible assets $ 27,202 $ 30,224 Amortization expense for the years ended December 31, 2021 and 2020 was $ 3,022 and $ 2,267 , respectively. Stock-Based Compensation The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to employees and non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted is re-measured each period. On March 24, 2015 and September 2, 2015, the Company granted 12,000,000 stock options to its employees and 3,950,000 stock options to its directors for services. On February 18, 2021, the Company granted 450,000,000 stock options to its employees for services at an exercise price of $ 0.091 . On June 29, 2021, the Company amended the exercise price of the options to $ 0.028 per share. The options expire, and all rights to purchase the shares shall terminate seven (7) years from the date of the repricing or upon termination of employment. Half of the 400,000,000 options vested upon grant, and the remaining half of the option to purchase 200,000,000 shares of the Company’s common stock shall become exercisable in equal amounts over a twenty-four ( 24 ) month period during the term of the optionee’s employment, with the first installment of 8,333,333 shares vesting on March 18, 2021. The 50,000,000 options are exercisable in equal amounts over a thirty-six ( 36 ) month period during the term of the optionee’s employment, with the first installment of 1,388,889 shares vesting on March 18, 2021. Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company used Black Scholes to value its stock option awards which incorporated the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life. The stock options terminate seven (7) years from the date of grant or upon termination of employment. As of December 31, 2021, 465,950,000 stock options were outstanding. Research and Development Research and development costs are expensed as incurred. Total research and development costs were $ 1,221,134 and $ 177,722 for the years ended December 31, 2021 and 2020, respectively. Net Earnings (Loss) per Share Calculations Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards (Note 4), plus the assumed conversion of convertible debt (Note 5).   For the year ended December 31, 2021, the Company has included shares issuable from 465,950,000 stock options and 223,958,334 warrants, because their impact on the income per share is dilutive. F- 7 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Net Earnings (Loss) per Share Calculations (Continued) For the year ended December 31, 2020 the Company’s diluted loss per share is the same as the basic loss per share, and the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. The Company has excluded 15,950,000 stock options, and the shares issuable from convertible debt of $ 2,739,790 , because their impact was anti-dilutive. SCHEDULE OF NET EARNINGS PER SHARE 2021 2020 For the Year Ended December 31, 2021 2020 Income (Loss) to common shareholders (Numerator) $ 10,189,480 $ ( 140,544,660 ) Basic weighted average number of common shares outstanding (Denominator) 651,573,767 280,952,034 Diluted weighted average number of common shares outstanding (Denominator) 1,117,523,767 280,952,034 Fair Value of Financial Instruments Fair Value of Financial Instruments requires disclosure of the fair value information, whether recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2021, the amounts reported for cash, inventory, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. We measure certain financial instruments at fair value on a recurring basis. As of December 31, 2021, there were no financial instruments to report. The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value: SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY FOR LEVEL 3 INPUTS Balance as of January 31, 2021 $ 148,590,100 Fair value of derivative liabilities issued 180,004 Fair value of derivative liability removed ( 178,736,187 ) Loss on change in derivative liability 29,966,083 Balance as of December 31, 2021 $ - F- 8 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Accounting for Derivatives The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Recently Issued Accounting Pronouncements In May 2021, the FASB issued an amendment to accounting standards ASU 2021-04, (Subtopic 470-50) – Debt Modifications and Extinguishments”, which requires that an entity apply the new guidance to a modification or an exchange of a freestanding equity-classified written call option that is a part of or directly related to a modification or an exchange of an existing debt. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company has evaluated the impact of the adoption of ASU 2021-04, which has no effect on the Company’s financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements. 3. CAPITAL STOCK Preferred Stock On January 14, 2021, the Board of Directors adopted a certificate of designation establishing the rights, preferences, privileges and other terms of 1,000 Series B Preferred Stock, par value $0.0001 per share, providing for supermajority voting rights to holders of the Series B Preferred Stock. The shares of the Series B Preferred Stock were issued to David Lee, Chief Executive Officer, Chairman of the Board, President and acting Chief Financial Officer. The Series B Preferred Stock total purchase price is $ 0.10 for 1,000 shares of Series B Preferred Stock. The Series B Preferred stock was returned and expired on February 28, 2021 . As of December 31, 2021, there were no shares outstanding. On April 14, 2021, the Board of Directors of the Company authorized the issuance of 1,000 shares of Series D Preferred Stock, par value $ 0.0001 per share, to David Lee, Chief Executive Officer, Chairman of the Board, President and acting Chief Financial Officer. The Series D Preferred Stock total purchase price was $ 0.10 for 1,000 shares of Series D Preferred Stock. The Series D Preferred stock was returned and expired on May 29, 2021 . As of December 31, 2021, there were no shares of Series D Preferred Stok outstanding. The Company estimated the fair value of the Series B and D Preferred Stock as of the valuation dates. The market approach was utilized to arrive at an indication of equity value by using quoted market prices of the common shares as of January 14, 2021 and April 14, 2021. The market cap of the Company represents 100% of the minority interest for all outstanding common shares. The Preferred Series B and D Preferred Stock fair value is based on the value of the voting rights. The Preferred Series B and D Preferred Stock represents a controlling voting interest in the Company and therefore determining the control premium is an indication of the security’s value. The control premium is based on publicly traded companies or comparable entities in related industries, which have been acquired in an arm’s-length transaction. The valuation of the Series B and D Preferred Stock were valued using the common stock price of $ 0.1587 and $ 0.0439 , respectively and the market capitalization based on the fully diluted common and preferred shares outstanding. The total fair value of the voting control of the Series B and Series D was $ 9,616,486 and $ 18,176,922 , respectively, for an aggregate total of $ 27,793,408 . On March 9, 2021, the Company entered into an agreement with an investor for the exchange of convertible debt to equity. The investor exchanged convertible notes in the amount of $ 2,462,060 , plus interest in the amount of $ 1,023,253 for an aggregate total of $ 3,485,313 for 34,853 shares of the Company’s Series C Preferred Stock with a stated face value of one hundred dollars ($ 100 ) (“share value”), and is convertible into shares of fully paid and non-assessable shares of common stock of the Company. The Series C preferred stock shall be entitled to receive dividends pari passu with the holders of common stock, except upon liquidation, dissolution and winding up of the Corporation. The Holder has the right, at any time, at its election, to convert shares of Series C Preferred Stock into common stock at a conversion price of $ 0.0014 , and has no voting rights. The extinguishment of the convertible debt was recognized in the Company’s financials as a gain on settlement of convertible notes and derivative. A valuation was prepared based on a stock price of $ 0.075 , with a volatility of 206.03 % , based on an estimated term of 5 years . SCHEDULE OF EXTINGUISHMENT OF DEBT Per Valuation Preferred shares issued 34,853 Stated value of debt and interest $ 3,485,313 Calculated fair value of preferred shares $ 85,555,201 Fair value of derivative liability removed $ 178,736,187 Gain $ ( 93,180,986 ) The Company recognized a gain on settlement of $ 93,180,986 for the extinguishment of convertible debt, plus derivative liability for the year ended December 31, 2021. F- 9 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 3. CAPITAL STOCK (Continued) Common Stock December 31, 2021 On June 10, 2021, the Company filed an amendment to its Articles of Incorporation to effect an increase in the authorized number of shares of common stock of the Corporation from 3,000,000,000 shares of common stock, par value $ 0.0001 per share to 6,000,000,000 shares of common stock, par value $ 0.0001 per share. During the year ended December 31, 2021, the Company issued an aggregate of 52,000,000 shares of common stock, pre-funded warrants to purchase up to 31,333,334 shares of common stock, and warrants to purchase up to 83,333,334 at an exercise price of $ 0.06 per share. During the year ended December 31, 2021, the Company issued 65,000,000 shares of common stock, pre-funded warrants to purchase up to 60,000,000 shares of common stock, and warrants to purchase up to 125,000,000 at an exercise price of $ 0.04 per shares. During the year ended December 31, 2021, the Company issued 21,964,188 shares of common stock upon conversion of convertible promissory notes in the principal amount of $ 184,124 , plus accrued interest of $ 20,851 , and other fees of $ 1,000 at prices ranging from $ 0.0014 - $ 0.0641 . During the year ended December 31, 2021, the Company issued 1,000,000 shares of common stock for services at fair value. During the year ended December 31, 2021, the Company issued 28,000,000 shares of common stock upon conversion of 392 shares of Series C Preferred stock. Common Stock December 31, 2020 During the year ended December 31, 2020, the Company issued 322,286,009 shares of common stock upon conversion of convertible promissory notes in the amount of $ 738,850 , plus accrued interest of $ 101,884 , and other fees of $ 4,750 at prices ranging from $ 0.0014 - $ 0.0074 . 4. STOCK OPTIONS Stock Options During the year ended December 31, 2021, the Company granted 400,000,000 stock options to its CEO and 50,000,000 stock options to an employee of the Company (See Note 2). SCHEDULE OF STOCK OPTIONS 12/31/2021 12/31/2020 Number of Options Weighted average exercise price Number of Options Weighted average exercise price Outstanding as of the beginning of the periods 15,950,000 $ 0.23 15,950,000 $ 0.23 Granted 450,000,000 $ 0.028 - - Exercised - - - - Expired - - Outstanding as of the end of the periods 465,950,000 $ 0.035 15,950,000 $ 0.23 Exercisable as of the end of the periods 313,172,222 $ 0.039 15,950,000 $ 0.23 F- 10 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 4. STOCK OPTIONS (Continued) The weighted average remaining contractual life of options outstanding as of December 31, 2021 and 2020 was as follows: SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OPTIONS OUTSTANDING 12/31/2021 12/31/2020 Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) $ 0.09 2,450,000 2,450,000 0.98 $ 0.09 2,450,000 2,450,000 1.23 $ 0.26 13,500,000 13,500,000 0.93 $ 0.26 13,500,000 13,500,000 1.37 $ 0.028 450,000,000 297,222,222 6.50 - - - - 465,950,000 313,172,222 15,950,000 15,950,000 The stock-based compensation expense recognized in the statement of operations during the years ended December 31, 2021 and 2020, related to the granting of these options was $ 22,438,794 and $ 0 , respectively. As of December 31, 2021 and 2020, respectively, there was no intrinsic value with regards to the outstanding options. 5. CONVERTIBLE PROMISSORY NOTES As of December 31, 2021, the Company had no outstanding convertible promissory notes. The Company issued an unsecured convertible promissory note (the May 2014 Note”), in the amount of $ 500,000 on May 2, 2014. The May Note matured on September 18, 2019 and was extended to May 2, 2022 on December 26, 2019. The May 2014 Note bears interest at 10 % per annum. The May 2014 Note is convertible into shares of the Company’s common stock at a conversion price of a) the lesser of $0.25 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the average three (3) lowest trading prices of three (3) separate trading days recorded after the effective date, or c) the lowest effective price granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The fair value of the May 2014 Note has been determined by using the Binomial lattice formula from the effective date of each tranche. During the year ended December 31, 2021, the Company exchanged principal of $ 1,560 , plus accrued interest of $ 970 for preferred stock. The May 2014 Note, as of December 31, 2021, was fully converted. The Company issued various unsecured convertible promissory notes (the 2015-2018 Notes”) in the aggregate amount of $ 2,145,000 on various dates of January 30, 2015 through February 9, 2018. The 2015-2018 Notes mature on January 30, 2023 . The 2015-2018 Notes bears interest at 10 % per annum. The 2015-2018 Notes are convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 to $0.25 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance within the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The fair value of the 2015-2018 Notes have been determined by using the Binomial lattice formula from the effective date of each tranche. During the year ended December 31, 2021, the Company exchanged the Note for Preferred Stock for principal in the amount of $ 1,960,500 , plus accrued interest of $ 923,717 . The 2015-2018 Notes, as of December 31, 2021, was fully converted. F- 11 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued various unsecured convertible promissory notes (the Feb 18 Note”) in the aggregate amount of $ 430,000 on various dates from February 26, 2018 through December 22, 2018. On January 13, 2021 and February 23, 2021, the Company received additional tranches in the amount of $ 70,000 , associated with the Feb 2018 Note for a total aggregate of $ 500,000 . The maturity date of the Feb 18 Note was extended, and as a result matures on February 18, 2023 . The Feb 18 Note bears interest at 10 % per annum. The Feb 18 Note is convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with-in the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The fair value of the Feb 18 Note was determined by using the Binomial lattice formula from the effective date of each tranche. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 126,134 during the year ended December 31, 2021. During the year ended December 31 2021, the Company exchanged the Note for Preferred Stock for principal in the amount of $ 500,000 , plus accrued interest of $ 98,566 . The Feb 18 Note, as of December 31, 2021, was fully converted. The Company issued an unsecured convertible promissory note on August 8, 2019 (the “August 2019 Note”), in the aggregate principal amount of $ 53,500 . The Company paid an original issue discount of $ 2,000 and received funds in the amount of $ 51,500 . The August 2019 Note shall mature on February 14, 2021 . The August 2019 Note bears interest at 10 % per annum. The August 2019 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest one (1) day trading price or lowest bid price during the fifteen (15) trading days prior to the conversion date. The parties agree that if shares of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the August 2019 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the August 2019 Note. The fair value of the August 2019 Notes has been determined by using the Binomial lattice formula from the effective date of the notes. The Company issued 21,000,000 shares of common stock upon conversion of principal in the amount of $ 40,676 , plus other fees of $ 3,000 . The August 2019 Note was converted based on the terms of the agreement and the Company did not recognize a gain or loss on conversion in the financials. During the year ended December 31, 2021, the Company issued 908,119 shares of common stock for principal in the amount of $ 12,824 , plus accrued interest of $ 5,564 and other fees of $ 1,000 . The August 2019 Note as of December 31, 2021, was fully converted. The Company issued an unsecured convertible promissory note on February 13, 2020 (the “Feb 2020 Note”), in the aggregate principal amount of $ 53,500 . The Company paid an original issue discount of $ 2,000 and received funds in the amount of $ 51,500 . The Feb 2020 Note matures on February 13, 2021 . The Feb 2020 Note bears interest at 10 % per annum. The Feb 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest one (1) day trading price or lowest bid price during the fifteen (15) trading days prior to the conversion date. The parties agree that if the shares of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Feb 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Feb 2020 Note. The fair value of the Feb 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. During the period ended September 30, 2021, the Company issued 6,479,947 shares of common stock for principal in the amount of $ 53,500 , plus accrued interest of $ 8,018 . The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 6,578 during the year ended December 31, 2021. The Feb 2020 Note as of December 31, 2021, was fully converted. F- 12 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued an unsecured convertible promissory note on July 6, 2020 (the Jul 2020 Note), in the aggregate principal amount of $ 53,000 . The Company paid an original issue discount of $ 3,000 and received funds in the amount of $ 50,000 . The Jul 2020 Note matures on July 6, 2021 . The Jul 2020 Note bears interest at 10 % per annum. The Jul 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Jul 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Jul 2020 Note. The fair value of the Jul 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 27,153 during the year ended December 31, 2021. The Company issued 4,062,044 shares of common stock upon conversion of principal in the amount of $ 53,000 , plus accrued interest of $ 2,650 . The Jul 2020 Note as of December 31, 2021, was fully converted. The Company issued an unsecured convertible promissory note on August 4, 2020 (the Aug 2020 Note), in the aggregate principal amount of $ 53,000 . The Company paid an original issue discount of $ 3,000 and received funds in the amount of $ 50,000 . The August 4, 2020 Note matures on August 4, 2021 . The Aug 2020 Note bears interest at 10 % per annum. The Aug 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Aug 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Aug 2020 Note. The fair value of the Aug 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 31,219 during the year ended December 31, 2021. The Company issued 868,175 shares of common stock upon conversion of principal in the amount of $ 53,000 , plus accrued interest of $ 2,650 . The Aug 2020 Note as of December 31, 2021 was fully converted. The Company issued an unsecured convertible promissory note on August 17, 2020 (the “Aug 2020 Note”), in the aggregate principal amount of $ 53,500 . The Company paid an original issue discount of $ 2,000 and received funds in the amount of $ 51,500 . The Aug 2020 Note matures on August 17, 2021 . The Aug 2020 Note bears interest at 10 % per annum. The Aug 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest one (1) day trading price or lowest bid price during the fifteen (15) trading days prior to the conversion date. The parties agree that if the shares of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Aug 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Aug 2020 Note. The fair value of the Aug 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. During the period the Company issued 6,440,677 shares of common stock upon conversion of principal in the amount of $ 53,500 , plus accrued interest of $ 5,350 . The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 33,566 during the year ended December 31, 2021. The Aug 2020 Note as of December 31, 2021, was fully converted. The Company issued an unsecured convertible promissory note on September 14, 2020 (the Sep 2020 Note), in the aggregate principal amount of $ 53,000 . The Company paid an original issue discount of $ 3,000 and received funds in the amount of $ 50,000 . The September 14, 2020 Note matures on September 14, 2021 . The Sep 2020 Note bears interest at 10 % per annum. The Sep 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Sep 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Sep 2020 Note. The fair value of the Sep 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 37,318 during the year ended December 31, 2021. The Company issued 2,100,000 shares of common stock upon conversion of principal in the amount of $ 53,000 , plus accrued interest of $ 2,650 . The Sep 2020 Note as of December 31, 2021, was fully converted. F- 13 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued an unsecured convertible promissory note on November 2, 2020 (the Nov 2020 Note), in the aggregate principal amount of $ 53,000 . The Company paid an original issue discount of $ 3,000 and received funds in the amount of $ 50,000 . The November 2, 2020 Note matures on November 2, 2021 . The Nov 2020 Note bears interest at 10 % per annum. The Nov 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Nov 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Nov 2020 Note. The fair value of the Nov 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 44,433 during the year ended December 31, 2021. The Note was paid off in cash for principal and interest. Company issued The Nov 2020 Note as of December 31, 2021, was fully converted. The Company issued an unsecured convertible promissory note on December 2, 2020 (the Dec 2020 Note), in the aggregate principal amount of $ 53,000 . The Company paid an original issue discount of $ 3,000 and received funds in the amount of $ 50,000 . The December 2, 2020 Note matures on December 2, 2021 . The Dec 2020 Note bears interest at 10 % per annum. The Dec 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Dec 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Dec 2020 Note. The fair value of the Dec 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 3,416 during the December 31, 2021. The Note was paid off in cash for principal and interest. The Dec 2020 Note as of December 31, 2021, was fully converted. The Company issued an unsecured convertible promissory note on January 4, 2021 (the Jan 4, 2021 Note), in the aggregate principal amount of $ 53,500 . The Company paid an original issue discount of $ 3,000 and received funds in the amount of $ 50,000 . The January 4, 2021 Note matures on March 4, 2021 . The Jan 2021 Note bears interest at 10 % per annum. The Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Jan 4 2021 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Jan 4 2021 Note. The fair value of the Jan 4 2021 Note has been determined by using the Binomial lattice formula from the effective date of the notes. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 53,500 during the year ended December 31, 2021. The Note was paid off in cash for principal and interest. The Jan 4, 2021 Note as of December 31, 2021, was fully converted. The Company issued an unsecured convertible promissory note on January 14, 2021 (the Jan 14 2021 Note), in the aggregate principal amount of $ 53,500 . The Company paid an original issue discount of $ 3,000 and received funds in the amount of $ 50,000 . The Jan 14 2021 Note matures on January 14, 2021 . The Jan 14 2021 Note bears interest at 10 % per annum. The Jan 14 2021 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Jan 14 2021 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Jan 14 2021 Note. The fair value of the Jan 14 2021 Note has been determined by using the Binomial lattice formula from the effective date of the notes. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 53,500 during the December 31, 2021. The Note was paid off in cash for principal and interest. The Jan 14 2021 Note as of December 31, 2021, was fully converted. F- 14 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 5. CONVERTIBLE PROMISSORY NOTES (Continued) During the year ended December 31, 2021, the Company exchanged convertible notes in the amount of $ 2,462,060 in principal, plus accrued interest of $ 1,023,253 for 34,853 shares of Series C Preferred Shares. In addition, the Company repaid convertible notes in the amount of $ 203,000 in principal, plus accrued interest of $ 52,780 . As of December 31, 2021, the Company had no outstanding convertible promissory notes. We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically per the stock price fluctuations. 6. DERIVATIVE LIABILITIES We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically per the stock price fluctuations. The convertible notes issued and described in Note 5 do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. During the year ended December 31, 2021, as a result of the convertible notes (“Notes”) issued that were accounted for as derivative liabilities, we determined that the fair value of the conversion feature of the convertible notes at issuance was $ 180,004 , based upon a Binomial-Model calculation. We recorded the full value of the derivative as a liability at issuance with an offset to valuation discount, which will be amortized over the life of the Notes. During the ended December 31, 2021, the Company converted $ 184,124 in principal of convertible notes, plus accrued interest of $ 20,851 , and other fees of $ 1,000 . The convertible notes were valued using the binomial lattice valuation model showing an increase in fair value of the derivatives issued by $ 638,936 and the loss on the change in derivatives by $ 29,966,084 . As of December 31, 2021, all derivatives were fully converted or paid off. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry-forward for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry-forward may be limited as to use in future years. F- 15 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 7. RELATED PARTY TRANSACTION On January 14, 2021, the Company issued 1,000 shares of Series B Preferred Stock to its CEO, David Lee. As of September 30, 2021, there were no Series B Preferred Stock outstanding. The total purchase price is $ 0.10 for 1,000 shares of Series B Preferred Stock. The Series B Preferred stock was returned and expired on January 29, 2021 . As of December 31, 2021, there were no shares of Series B outstanding. On April 14, 2021, the Company issued 1,000 shares of Series D Preferred Stock to its CEO, David Lee. The total purchase price is $ 0.10 for 1,000 shares of Series D Preferred Stock. The Series D Preferred stock was returned and expired on May 29, 2021 . As of December 31, 2021, there were no shares of Series D outstanding. 8. SECURITIES PURCHASE AGREEMENT On January 27, 2021, the Company entered into a securities purchase agreement with an investor to sell, through a private placement, an aggregate of 52,000,000 shares of common stock, pre-funded warrants to purchase up to 31,333,334 shares of common stock, and warrants to purchase up to 83,333,334 at an exercise price of $ 0.06 per share. In addition, the combined purchase price of $0.06 per one (1) share of common stock and associated warrant had a purchase price of $0.0599 per one (1) pre-funded and associated warrant for aggregate gross proceeds of $ 4,996,866 ( 50,000,000 assuming full exercise of the pre-funded warrants) for gross proceeds to the Company of approximately $ 5,000,000 . After closing cost, the Company received net funds of $ 4,406,217 , plus pre-funded proceeds of $ 3,133 for total cash received of $ 4,409,350 . In connection with the closing, the Company issued an additional 6,250,000 shares of warrants to purchase common stock with an exercise price of $ 0.075 which will expire on July 27, 2026 . On April 4, 2021, the Company entered into a securities purchase agreement with an investor to sell, through a direct registered offering, an aggregate of 65,000,000 shares of common stock, pre-funded warrants to purchase up to 60,000,000 shares of common stock, and warrants to purchase up to 125,000,000 at an exercise price of $ 0.04 per shares. In addition, the combined purchase price of $0.04 per one (1) share of common stock and associated warrant had a purchase price of $0.0399 per one (1) pre-funded and associated warrant for aggregate gross proceeds of $ 4,994,000 ( 50,000,000 assuming full exercise of the pre-funded warrants) for gross proceeds to the Company of approximately $ 5,000,000 . After closing cost, the Company received net funds of $ 4,369,350 , plus pre-funded proceeds of $ 6,000 for total cash received of $ 4,375,350 . In connection with the closing, the Company issued an additional 9,375,000 shares of warrants to purchase common stock with an exercise price of $ 0.05 and a termination date of April 4, 2026 . SCHEDULE OF WARRANTS ACITIVITY 12/31/2021 Number of Warrants Weighted average exercise price Outstanding as of the beginning of the periods - - Issued 315,291,668 $ 0.0482 Purchased ( 91,333,334 ) $ ( 0.0467 ) Expired - - Outstanding as of the end of the periods 223,958,334 $ 0.0488 Exercisable as of the end of the periods 223,958,334 $ 0.0488 The weighted average remaining contractual life of the warrants outstanding as of December 31, 2021 was as follows: SCHEDULE OF WARRANTS OUTSTANDING 12/31/2021 Exercisable Price Stock Warrants Outstanding Stock Warrants Exercisable Weighted Average Remaining Contractual Life (years) $ 0.04 125,000,000 125,000,000 4.27 $ 0.05 9,375,000 9,375,000 4.26 $ 0.06 83,333,334 83,333,334 4.57 $ 0.075 6,250,000 6,250,000 4.57 223,958,334 223,958,334 On April 7, 2021, the Company issued 125,000,000 warrants as an incentive, with an exercise price of $ 0.04 per share, and were valued at fair value of $ 5,983,504 using Black-Scholes. The warrants were deemed to be a dividend and were recognized in the financial statements. F- 16 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 9. COMMITMENTS AND CONTINGENCIES The Company rents office space on a yearly basis with a monthly rent payment in the amount of $ 550 . In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s financial position or results of operations. As of December 31, 2021, there were no legal proceedings against the Company. 10. INCOME TAXES On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”), which significantly changed U.S. tax law. The Act lowered the Company’s U.S. statutory federal income tax rate from 35 % to 21 % effective January 1, 2018. The Company files income tax returns in the U.S. Federal jurisdiction, and the state of California. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2018. Included in the balance at December 31, 2021, are no tax positions for which the ultimate deductibility is highly certain, but for which there is uncertainty about the timing of such deductibility. Because of the impact of deferred tax accounting, other than interest and penalties, the disallowance of the shorter deductibility period would not affect the annual effective tax rate but would accelerate the payment of cash to the taxing authority to an earlier period. The Company’s policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the year ended December 31, 2021, the Company did not recognize interest and penalties. As of December 31, 2021, the Company had net operating loss carry forwards of approximately $ 11,911,000 that may be offset against future taxable income. No tax benefit has been reported in the December 31, 2021 financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income tax rate to pretax income from continuing operations for the years ended December 31, 2021 and 2020 due to the following: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE 2021 2020 Book Income (Loss) 8,708,325 ( 29,514,380 ) Non-deductible expenses ( 9,153,120 ) 29,381,500 Valuation Allowance 444,799 132,880 Income tax expense $ - $ - Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the difference between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. F- 17 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020 10. INCOME TAXES Net deferred tax assets consist of the following components as of December 31, 2021 and 2020: SCHEDULE OF NET DEFERRED TAX ASSETS 2021 2020 Deferred tax assets: NOL carryover ( 2,501,390 ) ( 2,076,950 ) R & D credit 407,660 166,875 Depreciation 10,735 10,735 Deferred tax liabilities: - Less Valuation Allowance 2,082,995 1,899,340 Net deferred tax asset $ - $ - Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. 11. SUBSEQUENT EVENT Management has evaluated subsequent events according to the requirements of ASC TOPIC 855 and has reported the following subsequent events: On March 1, 2022, the Company issued 5,000,000 common stock purchase warrants for $ 1,000 , with an exercise price of $ 0.0255 per share subject to adjustment. The initial exercise date is March 1, 2024 , with a termination date of March 1, 2029 . On March 15, 2022, the Company granted 5,000,000 nonqualified stock options to a contractor, with an exercise price of $ 0.0223 per share. The Option shall vest at 138,888 per month over a thirty-six (36) month period from the grant date. The grant of the Option is made in consideration of the services to be rendered by the Optionee to the Company pursuant to an advisor agreement, or subsequent consecutive engagement by the Company as an employee, director, or consultant. The option granted under the advisor agreement expires ten ( 10 ) years from the date of grant, unless sooner. F- 18